Cleared Traditional

K252512 - Armada™ 14 NC PTA Catheter (FDA 510(k) Clearance)

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K252512 · Abbott Medical · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2026
Decision
186d
Days
Class 2
Risk

K252512 is an FDA 510(k) clearance for the Armada™ 14 NC PTA Catheter. Classified as Catheter, Angioplasty, Peripheral, Transluminal (product code LIT), Class II - Special Controls.

Submitted by Abbott Medical (Santa Clara, US). The FDA issued a Cleared decision on February 13, 2026 after a review of 186 days - an extended review cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1250 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Abbott Medical devices

Submission Details

510(k) Number K252512 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 11, 2025
Decision Date February 13, 2026
Days to Decision 186 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
61d slower than avg
Panel avg: 125d · This submission: 186d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LIT Catheter, Angioplasty, Peripheral, Transluminal
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - LIT Catheter, Angioplasty, Peripheral, Transluminal

All 401
Devices cleared under the same product code (LIT) and FDA review panel - the closest regulatory comparables to K252512.
Amethyst HP PTA OTW 0.035 Catheter
K251915 · Natec Medical , Ltd. · Dec 2025
Passeo-35 Xeo Peripheral Dilatation Catheter
K250706 · Biotronik, Inc. · Apr 2025
Parafleet SC 014 PTA Balloon Dilatation Catheter
K243704 · Brosmed Medical Co., Ltd. · Feb 2025
Amethyst HP PTA OTW 0.035 Catheter
K241040 · Natec Medical , Ltd. · Dec 2024
018 Hydrophilic Coated OTW PTA Balloon Dilatation Catheter
K242419 · Creagh Medical Ltd. Dba Surmodics, Inc. · Nov 2024
Finesse Injectable™ PTA Balloon Dilatation Catheter
K241740 · Summa Therapeutics · Jul 2024